2-indolinone errα inverse agonist and its pharmaceutical composition and application
A technology of indolinone and compound, applied in the field of medicinal chemistry, can solve the problems of restricting the development of ERRα inverse agonists, rare types, low druggability, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0148] Example 1 4-(4-((5-fluoro-1-(2-ethylmorpholine)-2-indolinone-3-ylide)methyl)-2-methoxyphenoxy)-3 -Trifluoromethylbenzonitrile (LS 1-86)
[0149] 4-(4-((5-fluoro-1-(2-morpholinoethyl)-2-oxoindolin-3-ylidene)methyl)-2-methoxyphenoxy)-3-(trifluoromethyl)benzonitrole
[0150]
[0151] Step 1 4-(4-Formyl-2-methoxyphenoxy)-3-(trifluoromethyl)benzonitrile (3)
[0152] 4-fluoro-3-(trifluoromethyl)benzonitrile (1,5g, 26.5mmol), vanillin (2,4g, 26mmol), potassium carbonate (6.1g, 44mmol) dissolved in anhydrous N,N- Dimethylformamide (50 mL), stirred overnight at room temperature. After the reaction was complete, ice water (200 mL) was added with stirring, and a large amount of solids precipitated out. It was filtered under reduced pressure and dried under vacuum to obtain a white solid (7.6 g, yield 92%).
[0153] 1 H NMR (400MHz, DMSO-d 6 ):δ10.02(s,1H),8.36(d,J=2.0Hz,1H),8.04(dd,J=8.4,2.0Hz,1H),7.72(d,J=2.0Hz,1H),7.66 (dd,J=8.0,2.0Hz,1H),7.45(d,J=8.4Hz,1H),6.95(d,J=8....
Embodiment 2
[0169] Example 2 4-(2-methoxy-4-((2-indolone-3-ylide)methyl)phenoxy)-3-trifluoromethylbenzonitrile (LS 1-61)
[0170] 4-(2-methoxy-4-((2-oxoindolin-3-ylidene)methyl)phenoxy)-3-(trifluoromethyl)benzonitrile
[0171]
[0172] The synthesis method is as in Example 1, step 2.
[0173] 1 H NMR (400MHz, DMSO-d 6 ):δ10.67(s,1H),10.63(s,0.9H),8.75(d,J=2.0Hz,1H),8.33(d,J=1.6Hz,1.8H),8.03(td,J= 8.8,2.0Hz,2H),7.95(dd,J=8.4,1.6Hz,1H),7.87(s,1H),7.73(d,J=7.6Hz,1H),7.69-7.62(m,1.8H) ,7.59(d,J=1.6Hz,0.9H),7.43(dd,J=8.8,1.6Hz,0.9H),7.36(d,J=8.4Hz,0.9H),7.31(d,J=8.4Hz ,1H),7.27-7.20(m,1.8H),7.05-6.96(m,2H),6.96-6.81(m,3.9H),3.80(s,3H),3.77(s,2.7H).
[0174] Further separation gave isomer A 1 H NMR (400MHz, DMSO-d 6 ):δ10.68(s,1H),8.76(d,J=2.0Hz,1H),8.34(d,J=1.6Hz,1H),8.03(dd,J=8.4,2.0Hz,1H),7.96 (dd,J=8.8,2.0Hz,1H),7.88(s,1H),7.74(d,J=7.2Hz,1H),7.32(d,J=8.4Hz,1H),7.24(td,J= 7.6Hz, 1.2Hz, 1H), 7.02(td, J=7.6Hz, 0.8Hz, 1H), 6.94(d, J=8.8Hz, 1H), 6.86(d, J=7.6Hz, 1H), 3.81( s,3H).
...
Embodiment 3
[0176] Example 3 4-(4-((5-bromo-1-H-2-indolone-3-ylide)methyl)-2-methoxyphenoxy)-3-trifluoromethylbenzyl Nitrile (LS 1-59)
[0177] 4-(4-((5-bromo-2-oxoindolin-3-ylidene)methyl)-2-methoxyphenoxy)-3-(trifluoromethyl)benzonitrole
[0178]
[0179] The synthesis method is as in Example 1, Step 2.
[0180] 1 H NMR (400MHz, DMSO-d 6 ):δ10.81(s,1H),10.80(s,0.4H),8.75(d,J=2.0Hz,1H),8.39-8.30(m,1.4H),8.11-7.93(m,3.8H) ,7.79-7.69(m,1H),7.63(s,0.6H),7.49-7.37(m,2.4H),7.33(d,J=8.4Hz,1H),6.96(dd,J=17.2,8.8Hz ,1.4H),6.90-6.77(m,1.4H),3.80(s,3H),3.79(s,1.2H).
[0181] MS(ESI):m / z 515[M+H] + .
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


